Metabolic syndrome and other factors associated with increased risk of diabetes

Engelgau, 2004, The evolving diabetes burden in the United States, Ann Intern Med, 140, 945, 10.7326/0003-4819-140-11-200406010-00035 Narayan, 2003, Lifetime risk for diabetes mellitus in the United States, JAMA, 290, 1884, 10.1001/jama.290.14.1884 Wild, 2004, Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030, Diabetes Care, 5, 1047, 10.2337/diacare.27.5.1047 Pinhas-Hamiel, 1996, Increased incidence of non-insulin-dependent diabetes mellitus among adolescents, J Pediatr, 128, 608, 10.1016/S0022-3476(96)80124-7 Macaluso, 2002, Type 2 diabetes mellitus among Florida children and adolescents, 1994 through 1998, Public Health Rep, 117, 373, 10.1016/S0033-3549(04)50174-7 Keenan, 2000, Are trends in diabetes incidence changing for minority children?, Ann Epidemiol, 10, 459, 10.1016/S1047-2797(00)00091-0 Gerich, 2003, Contributions of insulin-resistance and insulin- secretory defects to the pathogenesis of type 2 diabetes mellitus, Mayo Clin Proc, 78, 447, 10.4065/78.4.447 Hogan, 2003, Economic costs of diabetes in the US in 2002, Diabetes Care, 26, 917, 10.2337/diacare.26.3.917 Centers for Disease Control and Prevention Web site. Available at: Kannel, 1979, Diabetes and cardiovascular disease. The Framingham Study, JAMA, 241, 2035, 10.1001/jama.1979.03290450033020 2001, Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486 Lorenzo, 2003, The metabolic syndrome as predictor of type 2 diabetes: The San Antonio Heart Study, Diabetes Care, 26, 3153, 10.2337/diacare.26.11.3153 Zieve, 2004, The metabolic syndrome: Diagnosis and treatment, Clin Cornerstone, 6, S5, 10.1016/S1098-3597(04)80093-0 Reaven, 2003, Importance of identifying the overweight patient who will benefit the most by losing weight, Ann Intern Med, 138, 420, 10.7326/0003-4819-138-5-200303040-00012 Mclaughlin, 2004, Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals, Metabolism, 53, 495, 10.1016/j.metabol.2003.10.032 Laaksonen, 2002, Metabolic syndrome and development of diabetes mellitus: Application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study, Am J Epidemiol, 156, 1070, 10.1093/aje/kwf145 Nauck, 2003, A 25-year follow-up study of glucose tolerance in first-degree relatives of type 2 diabetic patients: Association of impaired or diabetic glucose tolerance with other components of the metabolic syndrome, Acta Diabetol, 40, 163, 10.1007/s00592-003-0106-y Mykkanen, 1993, Cardiovascular disease risk factors as predictors of type 2 (non-insulin-dependent) diabetes mellitus in elderly subjects, Diabetologia, 36, 553, 10.1007/BF02743273 Hanley, 2004, Metabolic and inflammation variable clusters and prediction of type 2 diabetes: Factor analysis using directly mea sured insulin sensitivity, Diabetes, 53, 1773, 10.2337/diabetes.53.7.1773 Hanley, 2003, Prediction of type 2 diabetes using simple measures of insulin resistance: Combined results from the San Antonio Heart Study, the Mexico City Diabetes Study, and the Insulin Resistance Atherosclerosis Study, Diabetes, 52, 463, 10.2337/diabetes.52.2.463 Sattar, 2003, Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study, Circulation, 108, 414, 10.1161/01.CIR.0000080897.52664.94 Klein, 2002, Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam, Diabetes Care, 25, 1790, 10.2337/diacare.25.10.1790 Meigs, 2004, Using metabolic syndrome traits for efficient detection of impaired glucose tolerance, Diabetes Care, 27, 1417, 10.2337/diacare.27.6.1417 Hanson, 2002, Components of the “metabolic syndrome” and incidence of type 2 diabetes, Diabetes, 51, 3120, 10.2337/diabetes.51.10.3120 Grundy, 2004, What is the contribution of obesity to the metabolic syndrome?, Endocrinol Metab Clin North Am, 33, 267, 10.1016/j.ecl.2004.03.001 Alberti, 1998, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation, Diabet Med, 15, 539, 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S Einhom, 2003, American College of Endocrinology position statement on the insulin resistance syndrome, Endocr Pract, 9, 237 Ruderman, 1981, The “metabolically-obese,” normal-weight individual, Am J Clin Nutr, 34, 1617, 10.1093/ajcn/34.8.1617 St-Onge, 2004, Metabolic syndrome in normal-weight Americans: New definition of the metabolically obese, normal-weight individual, Diabetes Care, 27, 2222, 10.2337/diacare.27.9.2222 Carey, 1996, Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM, Diabetes, 45, 633, 10.2337/diabetes.45.5.633 Snijder, 2003, Associations of hip and thigh circumferences independent of waist circumference with the incidence of type 2 diabetes: The Hoorn study, Am J Clin Nutr, 77, 1192, 10.1093/ajcn/77.5.1192 Carr, 2004, Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome, Diabetes, 53, 2087, 10.2337/diabetes.53.8.2087 Taniguchi, 2002, Relationship of regional adiposity to insulin resistance and serum triglyceride levels in nonobese Japanese type 2 diabetic patients, Metabolism, 51, 544, 10.1053/meta.2002.31984 Laaksonen, 2003, Relationships between changes in abdominal fat distribution and insulin sensitivity during a very low calorie diet in abdominally obese men and women, Nutr Metab Cardiovasc Dis, 13, 349, 10.1016/S0939-4753(03)80003-0 Tulloch-Reid, 2003, Do measures of body fat distribution provide information on the risk of type 2 diabetes in addition to measures of general obesity? Comparison of anthropometric predictors of type 2 diabetes in Pima Indians, Diabetes Care, 26, 2556, 10.2337/diacare.26.9.2556 Tripathy, 2000, Insulin secretion and insulin sensitivity in relation to glucose tolerance: Lessons from the Botnia study, Diabetes, 49, 975, 10.2337/diabetes.49.6.975 Bonora, 2004, Population-based incidence rates and risk factors for type 2 diabetes in white individuals: The Bruneck Study, Diabetes, 53, 1782, 10.2337/diabetes.53.7.1782 Grundy, 2004, Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition, Circulation, 109, 433, 10.1161/01.CIR.0000111245.75752.C6 Weyer, 1999, Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance, Diabetes, 48, 2197, 10.2337/diabetes.48.11.2197 Festa, 2004, Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose, Diabetes, 53, 1549, 10.2337/diabetes.53.6.1549 Hanefeld, 2003, Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: The risk factor in impaired glucose tolerance for atherosclerosis and diabetes study, Diabetes Care, 26, 868, 10.2337/diacare.26.3.868 Pontiroli, 2004, Evaluation of insulin release and insulin sensitivity through oral glucose tolerance test: Differences between NGT, IFG, IGT, and type 2 diabetes mellitus. A cross-sectional and follow-up study, Acta Diabetol, 41, 70, 10.1007/s00592-004-0147-x Larsson, 2000, Prediction of diabetes using ADA or WHO criteria in post-menopausal women: A 10-year follow-up study, Diabetologia, 43, 1224, 10.1007/s001250051516 Vaccaro, 1999, Risk of diabetes in the new diagnostic category of impaired fasting glucose: A prospective analysis, Diabetes Care, 22, 1490, 10.2337/diacare.22.9.1490 Genuth, 2003, Follow-up report on the diagnosis of diabetes mellitus, Diabetes Care, 26, 3160, 10.2337/diacare.26.11.3160 Borch-Johnsen, 2004, Creating a pandemic of prediabetes: The proposed new diagnostic criteria for impaired fasting glycaemia, Diabetologia, 47, 1396, 10.1007/s00125-004-1468-6 Shaat, 2004, Genotypic and phenotypic differences between Arabian and Scandinavian women with gestational diabetes mellitus, Diabetologia, 47, 878, 10.1007/s00125-004-1388-5 Albareda, 2003, Diabetes and abnormal glucose tolerance in women with previous gestational diabetes, Diabetes Care, 26, 1199, 10.2337/diacare.26.4.1199 Bian, 2000, Risk factors for development of diabetes mellitus in women with a history of gestational diabetes mellitus, Chin Med J (Engl), 113, 759 Di Cianni, 2003, Prevalence and risk factors for gestational diabetes assessed by universal screening, Diabetes Res Clin Pract, 62, 131, 10.1016/j.diabres.2003.07.004 Lauenborg, 2004, Increasing incidence of diabetes after gestational diabetes: A long-term follow-up in a Danish population, Diabetes Care, 27, 1194, 10.2337/diacare.27.5.1194 Dunaif, 1999, Insulin action in the polycystic ovary syndrome, Endocrinol Metab Clin North Am, 28, 341, 10.1016/S0889-8529(05)70073-6 Legro, 1999, Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women, J Clin Endocrinol Metab, 84, 165, 10.1210/jc.84.1.165 Oh, 2002, Endogenous sex hormones and the development of type 2 diabetes in older men and women: The Rancho Bernardo Study, Diabetes Care, 25, 55, 10.2337/diacare.25.1.55 Flier, 1985, Acanthosis nigricans in obese women with hyperandrogenism. Characterization of an insulin-resistant state distinct from the type A and B syndromes, Diabetes, 34, 101, 10.2337/diabetes.34.2.101 Litonjua, 2004, Prevalence of acanthosis nigricans in newly-diagnosed type 2 diabetes, Endocr Pract, 10, 101, 10.4158/EP.10.2.101 Marchesini, 2001, Nonalcoholic fatty liver disease: A feature of the metabolic syndrome, Diabetes, 50, 1844, 10.2337/diabetes.50.8.1844 Luyckx, 2000, Non-alcoholic steatohepatitis: Association with obesity and insulin resistance, and influence of weight loss, Diabetes Metab, 26, 98 Okamoto, 2003, The association of fatty liver and diabetes risk, J Epidemiol, 13, 15, 10.2188/jea.13.15 Lee, 2003, Gamma-glutamyl-transferase and diabetes-a 4 year follow-up study, Diabetologia, 46, 359, 10.1007/s00125-003-1036-5 Jiang, 2004, Body iron stores in relation to risk of type 2 diabetes in apparently healthy women, JAMA, 291, 711, 10.1001/jama.291.6.711 Harris, 1998, Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994, Diabetes Care, 21, 518, 10.2337/diacare.21.4.518 Park, 2003, The metabolic syndrome: Prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994, Arch Intern Med, 163, 427, 10.1001/archinte.163.4.427 Ferrannini, 2003, Influence of ethnicity and familial diabetes on glucose tolerance and insulin action: A physiological analysis, J Clin Endocrinol Metab, 88, 3251, 10.1210/jc.2002-021864 CE, 2004, Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?, Diabetes Care, 27, 1182, 10.2337/diacare.27.5.1182 Freeman, 2002, C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study, Diabetes, 51, 1596, 10.2337/diabetes.51.5.1596 Han, 2002, Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study, Diabetes Care, 25, 2016, 10.2337/diacare.25.11.2016 Thorand, 2003, C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: Results from the Monica Augsburg Cohort Study, 1984-1998, Arch Intern Med, 163, 93, 10.1001/archinte.163.1.93 Nakanishi, 2003, Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans, Diabetes Care, 26, 2754, 10.2337/diacare.26.10.2754 Tan, 2003, C-reactive protein predicts the deterioration of glycemia in Chinese subjects with impaired glucose tolerance, Diabetes Care, 26, 2323, 10.2337/diacare.26.8.2323 Hu, 2004, Inflammatory markers and risk of developing type 2 diabetes in women, Diabetes, 53, 693, 10.2337/diabetes.53.3.693 Pradhan, 2001, C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus, JAMA, 286, 327, 10.1001/jama.286.3.327 Duncan, 2004, Adiponectin and the development of type 2 diabetes: The Atherosclerosis Risk in Communities Study, Diabetes, 53, 2473, 10.2337/diabetes.53.9.2473 Spranger, 2003, Adiponectin and protection against type 2 diabetes mellitus, Lancet, 361, 226, 10.1016/S0140-6736(03)12255-6 Lindsay, 2002, Adiponectin and development of type 2 diabetes in the Pima Indian population, Lancet, 360, 57, 10.1016/S0140-6736(02)09335-2 Krakoff, 2003, Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian, Diabetes Care, 26, 1745, 10.2337/diacare.26.6.1745 Meigs, 2004, Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus, JAMA, 291, 1978, 10.1001/jama.291.16.1978 Norman, 2003, The impact of weight change on cardiovascular disease risk factors in young black and white adults: The Cardia Study, Int J Obes Relat Metab Disord, 27, 369, 10.1038/sj.ijo.0802243 Mokdad, 2001, The continuing epidemics of obesity and diabetes in the United States, JAMA, 286, 1195, 10.1001/jama.286.10.1195 Mokdad, 2000, Diabetes trends in the US: 1990-1998, Diabetes Care, 23, 1278, 10.2337/diacare.23.9.1278 Koh-Banerjee, 2004, Changes in body weight and body fat distribution as risk factors for clinical diabetes in US men, Am J Epidemiol, 159, 1150, 10.1093/aje/kwh167 Colditz, 1995, Weight gain as a risk factor for clinical diabetes mellitus in women, Ann Intern Med, 122, 481, 10.7326/0003-4819-122-7-199504010-00001 Resnick, 2000, Relation of weight gain and weight loss on subsequent diabetes risk in overweight adults, J Epidemiol Community Health, 54, 596, 10.1136/jech.54.8.596 Van Dam, 2002, Dietary patterns and risk for type 2 diabetes mellitus in US men, Ann Intern Med, 136, 201, 10.7326/0003-4819-136-3-200202050-00008 Salmeron, 2001, Dietary fat intake and risk of type 2 diabetes in women, Am J Clin Nutr, 73, 1019, 10.1093/ajcn/73.6.1019 Meyer, 2001, Dietary fat and incidence of type 2 diabetes in older Iowa women, Diabetes Care, 24, 1528, 10.2337/diacare.24.9.1528 Nkondjock, 2003, Fish-seafood consumption, obesity, and risk of type 2 diabetes: An ecological study, Diabetes Metab, 29, 635, 10.1016/S1262-3636(07)70080-0 Meyer, 2000, Carbohydrates, dietary fiber, and incident type 2 diabetes in older women, Am J Clin Nutr, 71, 921, 10.1093/ajcn/71.4.921 Mozaffarian, 2003, Cereal, fruit, and vegetable fiber intake and the risk of cardiovascular disease in elderly individuals, JAMA, 289, 1659, 10.1001/jama.289.13.1659 Liu, 2000, A prospective study of whole-grain intake and risk of type 2 diabetes mellitus in US women, Am J Public Health, 90, 1409, 10.2105/AJPH.90.9.1409 Ford, 2003, The metabolic syndrome and antioxidant concentrations: Findings from the Third National Health and Nutrition Examination Survey, Diabetes, 52, 2346, 10.2337/diabetes.52.9.2346 Lopez-Ridaura, 2004, Magnesium intake and risk of type 2 diabetes in men and women, Diabetes Care, 27, 134, 10.2337/diacare.27.1.134 Liu, 2003, Relation between changes in intakes of dietary fiber and grain products and changes in weight and development of obesity among middle-aged women, Am J Clin Nutr, 78, 920, 10.1093/ajcn/78.5.920 Janket, 2003, A prospective study of sugar intake and risk of type 2 diabetes in women, Diabetes Care, 26, 1008, 10.2337/diacare.26.4.1008 Salmeron, 1997, Dietary fiber, glycemic load,, and risk of NIDDM in men, Diabetes Care, 20, 545, 10.2337/diacare.20.4.545 Stevens, 2002, Dietary fiber intake and glycemic index and incidence of diabetes in African-American and white adults: The Aric Study, Diabetes Care, 25, 1715, 10.2337/diacare.25.10.1715 Schulze, 2004, Glycemic index, glycemic load, and dietary fiber intake and incidence of type 2 diabetes in younger and middleaged women, Am J Clin Nutr, 80, 348, 10.1093/ajcn/80.2.348 Stampfer, 1988, A prospective study of moderate alcohol drinking and risk of diabetes in women, Am J Epidemiol, 128, 549, 10.1093/oxfordjournals.aje.a115002 Nakanishi, 2003, Alcohol consumption and risk for development of impaired fasting glucose or type 2 diabetes in middle-aged Japanese men, Diabetes Care, 26, 48, 10.2337/diacare.26.1.48 Carlsson, 2003, Alcohol consumption and the incidence of type 2 diabetes: A 20-year follow-up of the Finnish Twin Cohort Study, Diabetes Care, 26, 2785, 10.2337/diacare.26.10.2785 Wannamethee, 2003, Alcohol drinking patterns and risk of type 2 diabetes mellitus among younger women, Arch Intern Med, 163, 1329, 10.1001/archinte.163.11.1329 Manson, 1992, A prospective study of exercise and incidence of diabetes among US male physicians, JAMA, 268, 63, 10.1001/jama.1992.03490010065031 Manson, 1991, Physical activity and incidence of non-insulindependent diabetes mellitus in women, Lancet, 338, 774, 10.1016/0140-6736(91)90664-B Wolf, 1994, Reproducibility and validity of a self-administered physical activity questionnaire, Int J Epidemiol, 23, 991, 10.1093/ije/23.5.991 Hu, 1999, Walking compared with vigorous physical activity and risk of type 2 diabetes in women: A prospective study, JAMA, 282, 1433, 10.1001/jama.282.15.1433 Hu, 2004, Physical activity, body mass index, and risk of type 2 diabetes in patients with normal or impaired glucose regulation, Arch Intern Med, 164, 892, 10.1001/archinte.164.8.892 Lynch, 1996, Moderately intense physical activities and high levels of cardiorespiratory fitness reduce the risk of non-insulin dependent diabetes mellitus in middle-aged men, Arch Intern Med, 156, 1307, 10.1001/archinte.1996.00440110073010 Wei, 1999, The association between cardiorespiratory fitness and impaired fasting glucose and type 2 diabetes mellitus in men, Ann Intern Med, 130, 89, 10.7326/0003-4819-130-2-199901190-00002 Sawada, 2003, Cardiorespiratory fitness and the incidence of type 2 diabetes: Prospective study of Japanese men, Diabetes Care, 26, 2918, 10.2337/diacare.26.10.2918 Camethon, 2003, Cardiorespiratory fitness in young adulthood and the development of cardiovascular disease risk factors, JAMA, 290, 3092, 10.1001/jama.290.23.3092 Hu, 2001, Physical activity and television watching in relation to risk for type 2 diabetes mellitus in men, Arch Intern Med, 161, 1542, 10.1001/archinte.161.12.1542 Hu, 2003, Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women, JAMA, 289, 1785, 10.1001/jama.289.14.1785 Rimm, 1995, Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men, BMJ, 310, 555, 10.1136/bmj.310.6979.555 Rimm, 1993, Cigarette smoking and the risk of diabetes in women, Am J Public Health, 83, 211, 10.2105/AJPH.83.2.211 Manson, 2000, A prospective study of cigarette smoking and the incidence of diabetes mellitus among US male physicians, Am J Med, 109, 538, 10.1016/S0002-9343(00)00568-4 Carnethon, 2003, Risk factors for progression to incident hyperinsulinemia: The Atherosclerosis Risk in Communities Study, 1987-1998, Am J Epidemiol, 158, 1058, 10.1093/aje/kwg260 Wannamethee, 2001, Smoking as a modifiable risk factor for type 2 diabetes in middle-aged men, Diabetes Care, 24, 1590, 10.2337/diacare.24.9.1590 Hu, 2001, Diet, lifestyle, and the risk of type 2 diabetes mellitus in women, N Engl J Med, 345, 790, 10.1056/NEJMoa010492 2002, Major outcomes in high-risk hypertensive patients random ized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), JAMA, 288, 2981, 10.1001/jama.288.23.2981 Hansson, 1999, Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) Randomised Trial, Lancet, 353, 611, 10.1016/S0140-6736(98)05012-0 Yusuf, 2001, Ramipril and the development of diabetes, JAMA, 286, 1882, 10.1001/jama.286.15.1882 Pepine, 2003, A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial, JAMA, 290, 2805, 10.1001/jama.290.21.2805 Lindholm, 2003, Metabolic outcome during 1 year in newly detected hypertensives: Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE Study), J Hypertens, 21, 1563, 10.1097/00004872-200308000-00022 Pfeffer, 2003, Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall Programme, Lancet, 362, 759, 10.1016/S0140-6736(03)14282-1 Dahlof, 2002, Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol, Lancet, 359, 995, 10.1016/S0140-6736(02)08089-3 Julius, 2004, Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial, Lancet, 363, 2022, 10.1016/S0140-6736(04)16451-9 2004, Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: The DREAM Trial, Diabetologia Prisant, 2004, Preventing type II diabetes mellitus, J Clin Pharmacol, 44, 406, 10.1177/0091270004263018 Brown, 2000, Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium channel blocker or diuretic in the International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment (INSIGHT), Lancet, 356, 366, 10.1016/S0140-6736(00)02527-7 Verdecchia, 2004, Adverse prognostic significance of new diabetes in treated hypertensive subjects, Hypertension, 43, 963, 10.1161/01.HYP.0000125726.92964.ab Ryan, 2003, Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia, Am J Psychiatry, 160, 284, 10.1176/appi.ajp.160.2.284 Clark, 2003, Diabetes mellitus associated with atypical anti-psychotic medications, Diabetes Technol Ther, 5, 669, 10.1089/152091503322250695 Gupta, 2003, Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy, Am J Ther, 10, 348, 10.1097/00045391-200309000-00007 Baptista, 2002, Obesity and related metabolic abnormalities during antipsychotic drug administration: Mechanisms, management and research perspectives, Pharmacopsychiatry, 35, 205, 10.1055/s-2002-36391 Lean, 2003, Patients on atypical antipsychotic drugs: Another high-risk group for type 2 diabetes, Diabetes Care, 26, 1597, 10.2337/diacare.26.5.1597 Lindenmayer, 2003, Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics, Am J Psychiatry, 160, 290, 10.1176/appi.ajp.160.2.290 Regenold, 2002, Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar, affective and schizoaffective disorders independent of psychotropic drug use, J Affect Disord, 70, 19, 10.1016/S0165-0327(01)00456-6 Marder, 2004, Physical health monitoring of patients with schizophrenia, Am J Psychiatry, 161, 1334, 10.1176/appi.ajp.161.8.1334 2004, Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes, J Clin Psychiatry, 65, 267, 10.4088/JCP.v65n0219 Kino, 2003, AIDS-related lipodystrophy/insulin resistance syndrome, Horm Metab Res, 35, 129, 10.1055/s-2003-39072 Butt, 2004, Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection, Hepatology, 40, 115, 10.1002/hep.20289 Calza, 2003, Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: Epidemiology, pathogenesis, clinical course and management, Int J Antimicrob Agents, 22, 89, 10.1016/S0924-8579(03)00115-8 Sax, 2004, Tolerability and safety of HIV protease inhibitors in adults, J Acquir Immune Defic Syndr, 37, 1111, 10.1097/01.qai.0000138420.38995.86 Woerle, 2003, Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens, Diabetes, 52, 918, 10.2337/diabetes.52.4.918 Hansen, 2004, Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: A review, Scand J Infect Dis, 36, 244, 10.1080/00365540410019381 Bucher, 2004, Protease inhibitor-sparing simplified maintenance therapy: A need for perspective, J Antimicrob Chemother, 54, 303, 10.1093/jac/dkh379 Kasiske, 2003, Diabetes mellitus after kidney transplantation in the United States, Am J Transplant, 3, 178, 10.1034/j.1600-6143.2003.00010.x Parikh, 2003, Obesity as an independent predictor of posttransplant diabetes mellitus, Transplant Proc, 35, 2922, 10.1016/j.transproceed.2003.10.074 Hernandez, 2003, Cardiovascular risk profile in nondiabetic renal transplant patients: Cyclosporine versus tacrolimus, Transplant Proc, 35, 1727, 10.1016/S0041-1345(03)00630-4 Heisel, 2004, New onset diabetes mellitus in patients receiving calcineurin inhibitors: A systematic review and meta-analysis, Am J Transplant, 4, 583, 10.1046/j.1600-6143.2003.00372.x Filler, 2000, Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients, Nephrol Dial Transplant, 15, 867, 10.1093/ndt/15.6.867 Montori, 2002, Posttransplantation diabetes: A systematic review of the literature, Diabetes Care, 25, 583, 10.2337/diacare.25.3.583 Pascual, 2003, A low incidence of new-onset insulin-dependent diabetes mellitus using tacrolimus in kidney recipients in Europe, Transplant Proc, 35, 1760, 10.1016/S0041-1345(03)00606-7 Nanji, 2004, Islet transplantation in patients with diabetes mellitus: Choice of immunosuppression, Biodrugs, 18, 315, 10.2165/00063030-200418050-00004 Davidson, 2003, New-onset diabetes after transplantation: 2003 international consensus guidelines. Proceedings of an international expert panel meeting, Barcelona, Spain, 19 February 2003, Transplantation, 75, S3 Li, 2002, Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: The Da Qing IGT and Diabetes Study, Diabetes Res Clin Pract, 58, 193, 10.1016/S0168-8227(02)00175-4 Tuomilehto, 2001, Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance, N Engl J Med, 344, 1343, 10.1056/NEJM200105033441801 Lindstrom, 2003, The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity, Diabetes Care, 26, 3230, 10.2337/diacare.26.12.3230 Lindstrom, 2003, Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: Results from a randomized clinical trial, J Am Soc Nephrol, 14, S108, 10.1097/01.ASN.0000070157.96264.13 Uusitupa, 2003, Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study, Diabetes, 52, 2532, 10.2337/diabetes.52.10.2532 1999, The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes, Diabetes Care, 22, 623, 10.2337/diacare.22.4.623 Knowler, 2002, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N Engl J Med, 346, 393, 10.1056/NEJMoa012512 2003, Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes, Diabetes Care, 26, 2518, 10.2337/diacare.26.9.2518 Hernan, 2003, Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program, Diabetes Care, 26, 36, 10.2337/diacare.26.1.36 Buchanan, 2002, Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women, Diabetes, 51, 2796, 10.2337/diabetes.51.9.2796 Torgerson, 2004, Xenical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients, Diabetes Care, 27, 155, 10.2337/diacare.27.1.155 1999, European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe, Lancet, 354, 617, 10.1016/S0140-6736(98)12131-1 Temelkova-Kurktschiev, 2000, Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or Hbalc level, Diabetes Care, 23, 1830, 10.2337/diacare.23.12.1830 Ceriello, 2004, Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hy pothesis revisited, Arterioscler Thromb Vasc Biol, 24, 816, 10.1161/01.ATV.0000122852.22604.78 Chiasson, 2002, Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial, Lancet, 359, 2072, 10.1016/S0140-6736(02)08905-5 Chiasson, 2004, Acarbose for the prevention of type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glu cose tolerance: Facts and interpretations concerning the critical analysis of the STOP-NIDDM trial data, Diabetologia, 47, 969, 10.1007/s00125-004-1409-4 Chiasson, 2003, Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tol erance: The STOP-NIDDM trial, JAMA, 290, 486, 10.1001/jama.290.4.486 Hanefeld, 2004, Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance, Stroke, 35, 1073, 10.1161/01.STR.0000125864.01546.f2 Hanefeld, 2004, Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: Meta-analysis of seven long-term studies, Eur Heart J, 25, 10, 10.1016/S0195-668X(03)00468-8 Esposito, 2004, Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus, Circulation, 110, 214, 10.1161/01.CIR.0000134501.57864.66